Background. The Food and Drug Administration (FDA) initiated a national strategy for monitoring post-market medical product safety using existing public and private electronic data. The Centers for Medicare and Medicaid Services (CMS) publicly report hospital central line-associated bloodstream infection (CLA-BSI) data. We explored the feasibility of expanding the current FDA Sentinel Initiatives on patient-level data to hospital-level data for surveillance of CLA-BSI associated with intravenous needleless connectors (NC).
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Methods. We merged the 2013 CMS Hospital Compare CLA-BSI data with the MaxPlus™ Tru-Swab™ Positive Displacement Connector (MP) client database from CareFusion to identify hospitals using the MPs (MP hospitals) vs those not using the MPs (Comparator hospitals). MP is a newer generation of NC with enhanced patient safety engineering design features. We evaluated CLA-BSI rates associated with MPs vs Comparators.
Results. In the CMS Hospital Compare CLA-BSI database, 3,074 hospitals reported central line (CL) days >1, with 25% (n = 758) hospitals using MP NCs. The MP hospitals accounted for 30% (2,923,859/ 9,887,264) 
